YZ is a manufacturing entity which produces and sells a range of products. YZ’s trial balance at 30 September 2020 is shown below:
Note R000 R000
Administrative expenses 910
Borrowings @ 7% per year 3,000
Buildings at cost at 30 September 2019 3,400
Cash and cash equivalents 130
Cash received on disposal of machinery (i) 8
Cost of raw materials purchased in year to 30 September 2020 2,220
Direct production labour costs 670
Distribution costs 515
Equity dividend paid 170
Equity shares R1 each, fully paid at 30 September 2020 (xi) 1,700
Income tax (viii) 30
Inventory of finished goods at 30 September 2019 (vii) 190
Inventory of raw materials at 30 September 2019 (vii) 275
Land at valuation at 30 September 2019 (ii) 9,000
Loan interest paid 210
Plant and equipment at cost at 30 September 2019 (i) 3,900
Production overheads (excluding depreciation) 710
Provision for deferred tax at 30 September 2019 (ix) 430
Accumulated depreciation at 30 September 2019:
Buildings (iii) 816
Plant and equipment (iv) 2,255
Patent (v) 526
Retained earnings at 30 September 2019 3,117
Revaluation reserve at 30 September 2019 1,800
Sales revenue 9,820
Share premium 100
Trade payables 940
Trade receivables 1,130 _____
23,986 23,986
Additional information:
i) During the year YZ disposed of obsolete machinery for R8,000. The cash received is included
in the trial balance. The obsolete machinery had originally cost R35,000 and had
accumulated depreciation of R32,000.
ii) On 30 September 2020 YZ revalued its land to R9,500,000.
iii) Buildings are depreciated at 2% per annum on the straight line basis. Buildings depreciation
should be treated as an administrative expense. No buildings were fully depreciated at 30
September 2019.
iv) Plant and equipment is depreciated at 25% per annum using the reducing balance method
and is treated as a production overhead.
v) The patent for one of YZ’s products was purchased on 1 October 2017. The patent had a useful life of 10 years when it was purchased and is being amortized on a straight line basis with no residual value anticipated.  amortization of the patent is treated as cost of sales when charged to the income statement. Research is carried out on a continuous basis to develop the patented process and ensure that the product range continues to meet customer
demands. The patent figure in the trial balance is made up as follows:
R000
Original cost of patent 420
less amortisation to 30 September 2019 (84)
336
Research costs incurred in the year to 30 September 2020
Total
190
526
vi) YZ’s accounting policy for amortisation and depreciation is to charge a full year in the year of
acquisition and none in the year of disposal.
vii) Inventory of raw materials at 30 September 2020 was R242,000. Inventory of finished goods
at 30 September 2020 was R180,000.
viii) The directors estimate the income tax charge on the year’s profits at R715,000. The balance
on the income tax account represents the under-provision for the previous year’s tax charge.
ix) The deferred tax provision is to be reduced by R47,000.
x) YZ entered into a non-cancellable 4 year operating lease on 1 October 2019, to acquire
machinery to replace the old machinery sold. Under the terms of the lease YZ will pay no rent
for the first year. R8,000 is payable for each of 3 years commencing on 1 October 2020. The
machine is estimated to have a useful economic life of 10 years.
xi) During the year YZ issued 200,000 R1 equity shares at a premium of 50%. The total
proceeds were received before 30 September 2020 and are reflected in the trial balance
figures.
Required:
Prepare YZ’s statement of comprehensive income and a statement of changes in equity for the year to 30 September 2020 and a statement of financial position at that date, in accordance with the requirements of International Financial Reporting Standards.
 

Answer rating: 100% (QA)

16 6700 17 YZ STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2020 ... View the full answer